This transformative merger creates a diversified CNS leader with significant scale and synergy potential. Traders should monitor the stock for spread-tightening as the deal progresses through regulatory and shareholder approvals, with the targeted Q4 2026 close. The fixed exchange ratio (1.5401) means relative performance of Indivior shares will directly impact the deal's value for Supernus holders.
Price Chart
Executive Summary
Supernus Pharmaceuticals has announced a definitive merger of equals with Indivior Pharmaceuticals in a 100% tax-free stock-for-stock transaction. Supernus shareholders will receive 1.5401 Indivior shares per Supernus share, with the combined company (Supernus, Inc.) creating a diversified CNS leader with ~$2.2B in pro forma net revenue and expected annual cost synergies of at least $125M. The transaction, targeted to close in Q4 2026, is subject to shareholder and regulatory approvals, with Indivior declaring a $1B special dividend to its pre-closing stockholders.
Key Facts
- Supernus shareholders to receive 1.5401 Indivior shares per Supernus share in a 100% tax-free stock-for-stock merger.
- Pro forma combined net revenue of $2,162M for the twelve months ended June 30, 2026.
- Expected annual cost synergies of at least $125 million.
- Pro forma Adjusted EBITDA of $888M, including synergies, with a 41% margin.
- Pro forma net leverage of <1x (0.99x) after adjusting for $650M of debt to fund the $1B special dividend.
- Combined company will have 11 medicines across 4 key therapeutic areas: addiction, ADHD, postpartum depression, and Parkinson's disease.
- Supernus CEO Jack Khattar will be President and CEO of the combined company, with a board split 4 directors from each company.
- Targeted close in Q4 2026, subject to shareholder and regulatory approvals.
- Indivior will declare a $1B aggregate dividend to pre-closing stockholders prior to closing.
- Supernus shareholders will own 43.5% of the combined company; Indivior shareholders 56.5%.
Financial Impact
Pro forma combined net revenue of $2,162M and Adjusted EBITDA of $888M (including $125M in cost synergies). The transaction is a stock-for-stock merger with no cash consideration to Supernus shareholders, but Indivior will pay a $1B special dividend to its own shareholders before closing.
Risk Factors
- Failure to obtain required shareholder approvals from either Supernus or Indivior.
- Regulatory delays or failure to obtain antitrust and other regulatory clearances.
- Integration risks and the possibility that anticipated $125M cost synergies are not fully realized.
- The $1B special dividend adds $650M in new debt to the combined company's balance sheet, increasing leverage.
- A competing or superior acquisition proposal could emerge, leading to termination fees.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (SUPN) — Batch item 1 | 0001104659-26-089526 |
| Document: tm2622009d4_8k.htm | 0001104659-26-089525 |
| Document: 0001104659-26-089526-index-headers.html | 0001104659-26-089526 |
| Document: 0001104659-26-089526-index.html | 0001104659-26-089526 |
| Document: 0001104659-26-089526.txt | 0001104659-26-089526 |
| 425 Filing (SUPN) — Batch item 6 | 0001104659-26-089525 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | DEFM14A | $41.49 $42.78 | ▲ +3.11% | ▲ +3.00% | $42.60 (+2.68%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.60 (−1.50%) |
Aug 3, 2026 8w ago | 8-K | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.60 (−1.50%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | DEFA14A / 425 / 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Jul 22, 2026 10w ago | 8-K | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.60 (−9.73%) |
Jul 22, 2026 10w ago | Press Release | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.60 (−9.73%) |
Jul 20, 2026 10w ago | Court Ruling | $47.42 $46.20 | ▼ −2.57% | ▼ −2.15% | $42.60 (−10.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access